Cancer Science & Therapy

Dalei Wang

Publications

• Case Report
  EGFR Primary T790M and L858R Double Mutation Confers Clinical Benefit to Erlotinib and Resistance to Osimertinib in One Lung Adenocarcinoma Patient: A Case Report
  Author(s): Xiaoai Zhao, Lingxiao Zhang, Le Wang, Zheling Chen, Pan Li, Andi Zhao, Jin Yang, Hua Dong, Lin Shi, Dalei Wang, Xiaochen Zhao, Yizhou Ye, Fugen Li and Zheng WangXiaoai Zhao, Lingxiao Zhang, Le Wang, Zheling Chen, Pan Li, Andi Zhao, Jin Yang, Hua Dong, Lin Shi, Dalei Wang, Xiaochen Zhao, Yizhou Ye, Fugen Li and Zheng Wang
  
  Introduction: EGFR TKI has been widely studied in both research and clinic. However, only few limited studies focus on EGFR primary resistance rather than acquired mutation. Usually, EGFR T790M mutation is resistant to first generation TKI (erlotinib, gefitinib) and sensitive to third generation TKI Osimertinib. Here, we report an EGFR primary T790M and L858R double mutation patient confers clinical benefit to Erlotinib and resistance to Osimertinib. Case presentation: Here we present a 70-year-old woman with lung adenocarcinoma harboredprimary T790M and L858R EGFR double mutation and underwent multiple lines of treatments. She benefited from the first-generation of EGFR TKI Erlotinib, and later quickly developed resistance to the third-generation TKI Osimertinib after disease progression, then followed a few rounds of chemotherapies. Multiple .. Read More»
  DOI: 10.4172/1948-5956.1000569

  Abstract PDF